NOVELTY - A genetically modified organism or cell line comprising an organism or cell line genetically engineered with an added gene for at least one carbon-fixing protein and at least one proton-pump protein, is new.    USE - The genetically modified organism or cell line is useful for producing organic compound, e.g. biologic or biofuel, where the biologic is selected from allergenics, antibodies, blood products or its derivative, enzymes, growth factors, hormones, immunomodulators, interferons, interleukins, polypeptides, proteins, serum, tissues, toxins and vaccines, where vaccine provides immunity from a disease selected from acquired immune deficiency syndrome, African swine fever, anthrax, bubonic plague, cervical cancer, chicken pox, Coxsackie, dengue fever, diphtheria, Ebola virus, echovirus, encephalitis, gastroenteritis, hepatitis, herpes, human immunodeficiency disease (HIV-1 or HIV-2), influenza, lower respiratory tract infection, Lyme disease, Marburg, measles, monkeypox, mumps, Norwalk virus infection, papillomavirus, parainfluenza, parvovirus, pertussis, picorna virus infection, pneumonia, pneumonic plague, polio, rabies, rotavirus infection, rubella, shingles, smallpox, swine flu, tetanus, tuberculosis, typhoids and yellow fever. The biologic is used for treating a condition selected from ankylosing spondylitis, autoimmune diseases, cancer, Crohn's disease, diabetes, gout, indeterminate colitis, inflammatory bowel disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, uveitis and viral infection (all claimed).    ADVANTAGE - Genetically modified organism or cell line is provided to increase the titer of a biologic or biofuel; to utilize alternative carbon sources as an energy resource; to increase production of biologic and biofuel; to increase the production of ATP and organic compounds without increasing production input; to increase ATP-dependent cellular functions; and to require fewer resources for growth and organic compound production.